PodcastPearls: Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

Commentary from Dr. Sunil Badve on Ki67 testing for patients with early-stage hormone receptor-positive/HER2-negative breast cancer from the American Society of Clinical Pathology (ASCP) and Clinical Care Options (CCO)

Sunil Badve, MD, FRCPath Released: December 28, 2021

Downloadable summary slideset with key data from the 2021 SABCS Symposium from Clinical Care Options (CCO)

From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD Vamsidhar Velcheti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: December 15, 2021 Expired: December 14, 2022

In this commentary from Clinical Care Options (CCO), experts look ahead to key studies being reported at SABCS 2021 and highlight what data they are most excited to see

Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Released: December 6, 2021